Biotech company Biogen (NASDAQ:BIIB) reported in Q4 CY2024, with sales up 2.9% year on year to $2.45 billion. Its non-GAAP ...

Biogen forecast 2025 profit below last year's levels and Wall Street expectations on Wednesday, hurt by a strong dollar and ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

Biogen Inc. closed 41.43% below its 52-week high of $238.00, which the company achieved on July 12th.

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

The symbol of Biogen Pharmachem Industries ... Niraj Vaghela is chairman and Khushboo Khandelwal is the company secretary for Biogen Pharmachem Industries Ltd. Zero income tax: Investment in ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oric Pharmaceuticals (ORIC – Research Report) ...

Biogen (BIIB) stock was granted a Market Perform recommendation by Bernstein ahead of Q4 earnings, citing concerns over its Alzheimer's drug sales. Read more here.

Biogen's Economic Impact: An Analysis Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges. Negative Revenue ...

Biogen (BIIB.O), opens new tab expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO said.